Kelemen E, Jánossa M, Triska E, Szalay F, Váradi A, Magyar T, Sellyei M
Leuk Res. 1985;9(8):1009-15. doi: 10.1016/0145-2126(85)90071-2.
In a preliminary study on five patients with accelerated CGL, transplantation of allogeneic matched bone marrow was shown to be feasible without whole-body irradiation. Animal experiments and studies with cells cultured in vitro suggest that the cytocastic drug used to kill leukaemic clones (Myelobromol-Chinoin) does not injure haemopoietic stroma. The administration of this protocol is cheap and easy. Our preconditioning does not, in itself, eradicate the malignant CGL clone immediately: 15-20% of marrow mitoses were Ph1+ one month after transplantation. For this reason, additional cytostatic therapy was given in the course of the 3rd to 6th post-transplant months. No Ph1+ cells were observed from the fourth post-transplant month onwards. Very few severe acute complications were seen and two out of three matched transplanted patients are disease-free 27 + and 13 + months later. On the basis of the developing normal spleen architecture and the changing pattern of circulating NAP score values, particularly the months-long persistence of distinctly low scores, and then the delayed emergence of normal levels, we put forward a hypothesis, emphasizing the role of environmental factors, including the formation of a normal haemopoietic stroma in the successfully transplanted CGL patient.
在一项针对5例加速期慢性粒细胞白血病(CGL)患者的初步研究中,结果显示,在不进行全身照射的情况下,移植配型相合的异体骨髓是可行的。动物实验以及体外细胞培养研究表明,用于杀死白血病克隆的细胞毒性药物(米洛溴铵-喹诺因)不会损伤造血基质。该方案的实施成本低廉且操作简便。我们的预处理本身并不能立即根除恶性CGL克隆:移植后1个月,15%-20%的骨髓有丝分裂细胞为Ph1阳性。因此,在移植后的第3至6个月期间进行了额外的细胞抑制治疗。从移植后第4个月起,未观察到Ph1阳性细胞。严重急性并发症极少出现,3例配型相合的移植患者中有2例在27个月和13个月后疾病无复发。基于正常脾脏结构的发展以及循环中性粒细胞碱性磷酸酶(NAP)评分值的变化模式,尤其是明显低评分持续数月,随后正常水平延迟出现,我们提出了一个假说,强调环境因素的作用,包括成功移植的CGL患者中正常造血基质的形成。